42nd Annual Miami Breast Cancer Conference® - Abstracts

home / journals / mbcc-suppl / 42nd-annual-miami-breast-cancer-conference---abstracts
87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer

87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer

Hope S. Rugo, MD;Sara M. Tolaney, MD, MPH;Nancy Chan;Erika P. Hamilton, MD;Eva Ciruelos;Ji-Yeon Kim;Elena López-Miranda;Elia Seguí;Neelima Vidula, MD;Joyce O’Shaughnessy, MD;Guiseppe Curigliano;Javier Cortés, MD;Alessandro Di Sanzo;Paula Muñoz Romero;Bartomeu Piza Vallespir;Manuel Dominguez;Kathy Puyana Theall;Alessandro Paoli;Monica Binaschi;Tomer Wasserman;Virginia Kaklamani, MD, DSc
April 24th 2025
ArticleMedical Oncology
88 Eflapegrastim, a Long-Acting Granulocyte Colony–Stimulating Factor, Administered the Same Day as Chemotherapy in Patients With Early-Stage Breast Cancer: Results From a Multicenter, Open-Label Study

88 Eflapegrastim, a Long-Acting Granulocyte Colony–Stimulating Factor, Administered the Same Day as Chemotherapy in Patients With Early-Stage Breast Cancer: Results From a Multicenter, Open-Label Study

Lee Schwartzberg, MD, FACP;Omkar Marathe;Shanta Chawla;Jeffrey L. Vacirca;Kenneth Crist;Howard Franklin;Manuel Modiano
April 23rd 2025
ArticleMedical Oncology
TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

BOLDSCIENCE;Pedram Razavi;Judith Balmaña;Stephen Luen;Mario Campone;Laura Cortesi;Norikazu Masuda;Kyong Hwa Park;Qingyuan Zhang;Emily Nizialek;Cathy Qi;Karen Cui;Sibylle Loibl;Mark Robson, MD;Filipa Lynce
April 22nd 2025
ArticleMedical Oncology
90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective

90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective

Atilla Soran, MD, MPH;Kazim Senol;Schlomo Schneebaum;Shigeru Imoto;Carole Mathelin;Alexander Mundinger;Meltem Selam;Vahit Ozmen
April 21st 2025
ArticleSurgical Oncology
91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer

91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer

Zeynep Ozlem Soran;Allison Brophy;Lily Kass;Berkay Demirors;Hayeon Kim;Atilla Soran, MD, MPH;John Austin Vargo;Parul Barry
April 20th 2025
ArticleImaging and Radiology
92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

Michelle Sosa;Deirdre McNicholas;Arbelina Bebla;Seth Emont;Zhun Cao;Manu Tyagi;Craig Lipkin;Sommer Gunia
April 19th 2025
ArticleImaging and Radiology
96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

Elyse Swallow;Jessica Maitland;Kirthana Sarathy;Ellen Sears;Yasir Nagarwala;Janelle DePalantino;Eric Kruep;Corey Pelletier;Sebastian Kloss;Tomer Wasserman
April 18th 2025
ArticleMedical Oncology
97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

Chia Jie Tan;Connor Willis;Trang Au;Matthew Schabath, PhD;Chenghui Li;Kristen Kelley;Xiaoqing Xu;Leah Park;Clara Lam;Sandhya Mehta;Jackie Kwong;Diana Brixner;David Stenehjem
April 17th 2025
ArticleMedical Oncology
TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

Sara M. Tolaney, MD, MPH;Paolo D’Amico;Liyi Jia;Kim M. Hirshfield;Fatima Cardoso
April 16th 2025
ArticleMedical Oncology
100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey

100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey

Alexandra Vitko;Pamela K Ginex;Kelli Thoele;Qinli Lily Ma;Astra Liepa;Wambui Gathirua-Mwangi;Elyse Hall Panjic, PharmD, BCOP;Engels Chou;Jodi L Taraba;Hilary Ellis;Charlotte Clewes;Joanna de Courcy;Hope S. Rugo, MD
April 15th 2025
ArticleMedical Oncology
102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

Charlotta Wadsten;Karuna Mittal;Pat W. Whitworth;Chirag Shah, MD;Frank Vicini, MD;Naamit Gerber;Melissa Krystel-Whittemore;Clayton C. Yates;Balasubramanyam Karanam;Walter Bell;Charles E. Cox, MS, FACS;Abigail Beard;Geza Acs;Steven C. Shivers;David J. Dabbs;Jess Savala;Mark Mentrikoski;Troy Bremer
April 14th 2025
ArticleMedical Oncology
103 Leveraging Digital Technology to Improve Breast Cancer Patients’ Understanding of Treatment Recommendations

103 Leveraging Digital Technology to Improve Breast Cancer Patients’ Understanding of Treatment Recommendations

Caroline Welsh;Nicole Taylor;Julie Cole;Manjeet Chadha
April 13th 2025
ArticleMultidisciplinary Specialties
104 Identification of Ductal Carcinoma In Situ Patients With Low-Risk Clinicopathology Who Benefit From Radiation Therapy With and Without Endocrine Therapy After Breast-Conserving Surgery Assessed With the 7-Gene Biosignature

104 Identification of Ductal Carcinoma In Situ Patients With Low-Risk Clinicopathology Who Benefit From Radiation Therapy With and Without Endocrine Therapy After Breast-Conserving Surgery Assessed With the 7-Gene Biosignature

Pat W. Whitworth;Chirag Shah, MD;Frank Vicini, MD;Rachel Rabinovitch, MD;Julie A. Margenthaler, MD;Fredrik Warnberg;Micheal Leo;Sheila Weinmann;G. Bruce Mann;David J. Dabbs;Jess Savala;Steven C. Shivers;Karuna Mittal;Troy Bremer
April 12th 2025
ArticleImaging and Radiology
TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study

TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study

Pooja Advani, MBBS, MD;Sofia Braga;Adam M. Brufsky, MD, PhD;Karthik V. Giridhar;Erica L. Mayer, MD, MPH;Kelly E. McCann;Ruth M. O’Regan;Cristina Saura;Seth A. Wander;Georg F. Bischof;Beth H. Lowenthal;Judith D. Bebchuk;Lisa D. Eli;Brian G. Barnett;Joyce A. O’Shaughnessy;Tufia C. Haddad
April 11th 2025
ArticleMedical Oncology
106 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Interim Analysis of the Multinational, Prospective, Noninterventional Study ELEANOR (N=300)

106 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Interim Analysis of the Multinational, Prospective, Noninterventional Study ELEANOR (N=300)

Reshma L. Mahtani, DO ;Diana Lüftner;Denise Wrobel;Dagmar Guth;Matthias Zaiss;Jürgen Terhaag;Mark-Oliver Zahn;Lidia Pervola-Griff;Andrea Distelrath;Rachel Würstlein;Jörg Thomalla;Klaus Apel;Natalija Deuerling;Timo Schinköthe;Corinne Vannier;Rupert Bartsch;Christian Jackisch;Volkmar Müller;Marcus Schmidt;Marija Balic;Gabriel Rinnerthaler;Urs Breitenstein;Khalil Zaman;Michael Schwitter;Nadia Harbeck, MD, PhD
April 10th 2025
ArticleMedical Oncology
107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

Sarah Sammons;Rachel A. Freedman;Adam M. Brufsky;Ahmad Awada;Sara A. Hurvitz, MD;Nancy U. Lin, MD;Cristina Saura;Sheri Leung;Bethann S Hromatka
April 9th 2025
ArticleMedical Oncology